Meeting
2022 ASCO Genitourinary Cancers Symposium
Real-world evidence from a single U.K. cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.
Authors
Syed A. Hussain
Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom
Syed A. Hussain , Muneeb Qureshi , Bilal Tahir , Ahmed Rehan , James W.F. Catto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 461)
DOI
10.1200/JCO.2022.40.6_suppl.461
Abstract #
461
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing.
First Author: Ali Raza Khaki
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.
First Author: Carissa Beaulieu
Poster
2023 ASCO Annual Meeting
Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.
First Author: Konrad Stawiski
Poster
2023 ASCO Genitourinary Cancers Symposium
High-dose chemotherapy with autologous stem cell transplant (HDCT) for patients (pts) with advanced germ-cell tumors (aGCT): Real-world evidence from a tertiary cancer center in Brazil.
First Author: Gabriel Berlingieri Polho